76results about How to "Reduce addiction" patented technology

A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof; a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline; and, various methods of manufacturing or forming an immediate dosage form of varenicline.

A composition for nasal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient. The invention also provides a composition for buccal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient to form a solid dosage form, wherein the solid dosage form disintegrates in an oral cavity at body temperature and may adhere to body tissue of the oral cavity; a composition for pulmonary administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient; and, a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject.

Disclosed herein is the use of chemical irritants, such as vanilloid receptor-1 agonists, in sustained/controlled release pharmaceutical preparations which also contain a drug typically having high abuse potential. Inclusion of the VR1 agonist in the pharmaceutical preparation interferes with illicit or inappropriate dosing without significantly interfering with the action of the therapeutic. Also disclosed are exemplary co-formulations of capsaicin (a VR1 agonist) and oxycodone (an opioid therapeutic having high abuse potential) in controlled release preparations.

The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

The invention provides chimeric peptide based on endomorphins 2 and neuropeptides FF, wherein the chimeric peptide is the novel chimeric peptide EN-9 which is constructed by using the characteristic that both a C end of the endomorphins 2 and an N end of the neuropeptides FF have phenylalanine residues, on the basis of reserving an N end structure of the endomorphins 2 and a C end structure of the neuropeptides FF. Through in-vivo pharmacological study, it is found that the EN-9 shows stronger and more persistent analgesic activity than the endomorphins 2, and has the advantages of no enduring action, low addiction and the like. In addition, hypodermic compound EN-9 can play obvious analgesic action, can overcome the defect that the endomorphins have no analgesic activity through injecting in peripheral regions, therefore the chimeric peptide has a potential using value of being used for clinical pain treatment.

Pharmaceutical composition and food comprising edible carboxylic acid and/or its acidic salt and optionally caffeine, crude drug and pharmaceutical acceptable carrier are disclosed. The invention also discloses the use and method of composition or food. The composition or food of the present invention can prevent, treat or relief allergy, ache, cold, viral infection, thrombus or clotting, inflammation, cancer, intoxication, memory decay, caffeine dependence. The invention also relates to feedstuff for animals.

The invention is a patch or other applicator, or other method of administration, and a process to concept is to utilize patches (or other methods of delivery), that may contain nicotine in addition to, and that contain other chemicals that have been shown, or will be shown, either by subjective or objective measures, to increase “impact” (an tobacco industry term for the subjective awareness by the smoker of the drug effects of nicotine), or to increase addiction. Chemicals that decrease addiction behavior, or decrease signs and symptoms of withdrawal from the addictive substance or behavior may also be included. The claimed methods have application in the treatment of addiction to tobacco products, addiction to alcohol, and other addictions.

The invention discloses an oral prednisone time-selecting release preparation and a preparation method thereof. The oral prednisone time-selecting release preparation provided by the invention mainly consists of 0.3-5 parts of prednisone and derivatives thereof, 10-50 parts of glyceryl behenate and 3-30 parts of hydroxypropyl cellulose, and can further contain a disintegrating agent and other pharmaceutically acceptable excipients. The preparation method is as below: extruding tablet cores or granules containing the drug according to the formula by a tablet press or a dry granulator; and coating the tablet cores or particles containing the drug by a coating pan or a fluidized bed to attach the coating film to the tablet cores or particles containing the drug, so as to obtain the oral prednisone time-selecting release preparation. The oral prednisone time-selecting release preparation provided by the invention can achieve a good balance between the biological rhythm of the patients and the curative effects, and is safer, more convenient and effective compared with a traditional preparation. The oral prednisone time-selecting release preparation is prepared by an extrusion-coating process, which is simple for operation, and the obtained time-selecting release preparation has the advantages of drug stability and high reproducibility.

A chewing gum composition including a water insoluble base portion; a water soluble portion; and a therapeutically effective amount of varenicline or its pharmaceutical acceptable salt thereof. A method for reducing nicotine addiction and aiding in the cessation or lessening of tobacco use in an individual by administering to an oral cavity of an individual a chewing gum composition including an effective amount of varenicline or its pharmaceutical acceptable salt thereof; and chewing the gum composition to cause the varenicline or its pharmaceutical acceptable salt thereof to be released from the chewing gum composition into the oral cavity of the individual. A method of manufacturing a chewing gum composition.

The invention belongs to the field of pharmaceutical science, and particularly relates to a doxycycline hydrochloride dual-release preparation and a preparation method thereof. The preparation consists of micropills with different release performance, namely the preparation is formed by mixing 50 to 85 weight percent of quick-release micropill and 50 to 15 weight percent of sustained-release micropill. The preparation method comprises the following steps of: preparing micropill cores according to a formula, and preparing the quick-release micropills by using the micropill cores; preparing thesustained-release micropills by using the quick-release micropills; and filling the quick-release micropills and the sustained-release micropills into capsules in a ratio to obtain doxycycline hydrochloride dual-release capsules. Pharmacokinetic experiments in the dual-release capsule bodies indicate that medicines in the doxycycline hydrochloride dual-release capsules can be released twice when the doxycycline hydrochloride dual-release capsules are taken once every day, and the concentration of two-time peaks is close; the concentration peak of medicines in blood plasma is reduced by a dual-release model, the possibility of side effect is reduced, and the compliance of the administration of patients is improved; and due to the adoption of a new formula and a new process, the difference among batches is reduced, and the stability of samples is improved, so the doxycycline hydrochloride dual-release preparation is suitable for industrial production.

The present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to phencyclidine (PCP). The method includes administering to the mammal an effective amount of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of PCP.

The present invention relates to methods of drug-assisted psychotherapy with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects undergoing psychotherapeutic intervention. In particular, methods and kits for drug-assisted psychotherapy with 3-MMC for a variety of disorders and/or conditions, including PTSD, GAD and relationship distress are provided.

The invention discloses a heat-not-burn plant particle with a damp-proof layer and a preparation method of the heat-not-burn plant particle. The heat-not-burn plant particle is prepared from the following components in parts by weight: 40-80 parts of plant particles, 10-40 parts of fragrant substances, 10-50 parts of a smoke agent and 10-20 parts of the damp-proof layer. The preparation method comprises the following steps: taking medicinal and edible plants, crushing, sieving, granulating and drying to obtain plant particles; mixing the plant particles with a fragrant substance and a smoke agent, uniformly spraying the moisture-proof coating liquid on the surfaces of the plant particles, and drying at low temperature to obtain the heat-not-burn plant particles with the moisture-proof layer. The obtained heat-not-burn plant particles are good in moisture-proof effect, do not affect aerosol release, are simple in process and have certain industrial application value, and a coating material is easy to obtain.

The invention discloses a caffeine-containing fuming particle. The caffeine-containing fuming particle comprises the following components in parts by weight: 30-70 parts of plant raw materials, 10-40parts of fuming agent and 0.001-1 part of caffeine-containing component. The invention further discloses a preparation method of the fuming particle and a low-temperature heating incombustible productprepared from the fuming particle. By adopting the formula of the caffeine-containing components and natural plant raw materials, the fuming particle can replace the tobacco containing nicotine, an effect of refreshing and decompressing can be realized while reducing the addiction and health hazard; the fuming particle is convenient to carry and use in a solid particle manner, and the problem that the carry is inconvenient since the atomized liquid is easy to leak can be avoided.

The invention discloses codein and chlorphenamine compound sustained release capsules. The sustained release granules are made from the following raw materials by weight: 10-11.1 parts of codein, 2-2.2 parts of chlorphenamine, 1-2 parts of a lubricant, 18.9-86 parts of a sustained release matrix material and 0-12.4 parts of a filling agent. The sustained release matrix material is two or three of hydroxypropyl emthylcellulose, acrylic resin and ethyl cellulose, wherein, the acrylic resin and the ethyl cellulose totally accounts for 10.9-31.5%. The capsules are obtained by the following steps: evenly mixing the codein, the chlorphenamine and the sustained release matrix material; adding a binder to prepare a soft material and sieving with a 6-24-mesh sieve; preparing damp granules, drying and granulating; and adding the lubricant, evenly mixing and then encapsulating to obtain the finished product.

The invention relates to a pH-independent zaleplon-based dipulse release capsule and a method for preparing the same. The contents of the Zaleplon-based dipulse release capsule comprise a quick-release tablet and a timed-release tablet, wherein the quick-release tablet is prepared from the following components in parts by weight: 50-200 parts of zaleplon, 220-880 parts of a filler, 10-40 parts of a binder, 15-60 parts of a disintegrant and 5-20 parts of a lubricant; the timed-release tablet comprises a medicine core and a coating, and the medicine core is prepared from the following components in parts by weight: 125-500 parts of zaleplon, 168-675 parts of a filler, 0-100 parts of a binder, 50-200 parts of a disintegrant and 6-26 parts of a lubricant.

The invention discloses a method for achieving voice interaction/man-robot conversation of an accompanying robot. The method comprises the following steps that a user gives an instruction to the accompanying robot through a main silicon wheat board/key, the accompanying robot transmits conversation content to a mainboard baseband chip module through an audio module, and character searching is conducted on voice semantics of the conversation content through the mainboard baseband chip module; character searching content is synthesized through baseband signal codes and transmitted to a cloud platform knowledge base through WIFI network signals/base station signals, and corresponding content is acquired from the cloud platform knowledge base, decoded through the baseband signal codes and transmitted to the audio module through the WIFI network signals/base station signals for voice reduction and audio reduction; and reduced content is played through a voice output module, and man-robot voice interaction is achieved. According to the method, a voice technology is adopted, man-robot voice interaction is achieved, a cloud platform database is connected, and the content needed by consumers is selectively searched through a big database technology.

The invention discloses a terminal control method, an intelligent terminal and a device with a storage function. The method comprises the steps of enabling wearable equipment to judge whether an authorization request from a controlled terminal is received or not, and the authorization request comprising an authorization request of the controlled terminal for carrying out a preset risk operation; if the authorization request is received, displaying the authorization request to the user, and sending prompt information about whether to authorize or not; judging whether an authorization confirmation instruction input by the user is received or not, wherein the user is a user of the wearable equipment; and if the authorization confirmation instruction is received, sending authorization confirmation information to the controlled terminal so as to open the operation authority of the preset risk operation corresponding to the controlled terminal. By means of the mode, the possibility that a child is addicted to terminal equipment such as a mobile phone or carries out risk operation such as payment can be reduced, and parents can know more entertainment activities of the child.

Method for a deep and repetitive transcranial magnetic stimulation of an individual by means of magnetic pulses applied at least to a region of the scalp of the individual, said region being at least the bilateral prefrontal cortex, preferably the bilateral prefrontal cortex and the insula, the method comprising the steps of determining a threshold intensity of said magnetic pulses by applying to the individual one or more reference magnetic stimulations and determining a reaction of the individual to said reference stimulation, wherein said reaction corresponds to a right thumb movement and repeatedly applying a magnetic stimulation for at least 80 trains per session for a duration not exceeding 2 seconds each with a time interval between a train application and the next one not less than 20 seconds, wherein said magnetic stimulation has a frequency of at least 18 Hz with an intensity of stimulation at least 120% of the threshold intensity.